FHTX

Foghorn Therapeutics Inc. (FHTX) - 10-Q Summary

Business Context and Reporting Period

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines targeting the chromatin regulatory system. This report covers the quarterly period ended June 30, 2026. The company operates as a single segment focused on its proprietary Gene Traffic Control platform and a strategic collaboration with Eli Lilly and Company ("Lilly").

Key Financial Metrics (Six Months Ended June 30, 2026)

Note: The filing does not provide a specific "gross margin" or "operating margin" percentage; the company is pre-commercial with no product sales revenue.

Material Changes vs. Prior Period

• Revenue Increase: Collaboration revenue increased to $19.3 million for the six months ended June 30, 2026, from $13.5 million in the prior year period. This increase was primarily driven by a $14.2 million cumulative catch-up adjustment to reflect updated future costs due to the scheduled expiration of the research term in December 2026.
• Expense Reduction: Total operating expenses decreased by $7.8 million year-over-year.
  • R&D Expenses: Decreased by $6.6 million, driven by lower costs for Lilly partnered programs ($6.8M decrease) and the discontinuation of the FHD-286 program ($1.4M decrease). This was partially offset by a $6.1 million increase in early development and platform research costs.
  • G&A Expenses: Decreased by $1.2 million, primarily due to reduced rent and building maintenance costs associated with a new office lease in Watertown, Massachusetts.
• Capital Raise: In January 2026, the company completed an offering raising approximately $50.0 million in gross proceeds through the sale of common stock, pre-funded warrants, and series warrants.
• Other Income: Other income, net, decreased significantly due to the conclusion of sublease income in 2025 and lower interest income from marketable securities.

Guidance, Outlook, and Risks

• Liquidity: As of June 30, 2026, the company held $167.6 million in cash, cash equivalents, and marketable securities. Management expects these resources to fund operations for at least 12 months from the issuance date of the report.
• Outlook: The company expects to continue incurring significant operating losses. Future expenses are projected to increase as the company advances the Phase 1 clinical trial of FHD-909 (partnered with Lilly) and expands its discovery pipeline.
• Key Risks:
  • Capital Requirements: The company will need additional funding through equity, debt, or collaborations to sustain operations beyond the next 12 months.
  • Development Uncertainty: No products are approved for sale; success depends on clinical trial outcomes and regulatory approvals.
  • Revenue Recognition: Future revenue recognition is sensitive to estimates of total costs to complete the Lilly collaboration performance obligation.
  • IRS Audit: The company is currently under an IRS audit for the tax year ended December 31, 2023.

Investor Verification Checklist

• Revenue Adjustment: Verify the impact of the $14.2 million catch-up adjustment on future revenue recognition rates and the remaining deferred revenue balance ($229.8 million).
• Cash Burn Rate: Confirm the 12-month liquidity runway given the net cash used in operating activities of $43.1 million for the six-month period.
• Program Status: Review the status of the FHD-909 Phase 1 trial and the rationale for discontinuing the FHD-286 program.
• Warrant Dilution: Assess the potential dilution from the 7.45 million Series Warrants and 5.42 million Pre-Funded Warrants issued in the January 2026 offering.
• IRS Audit Outcome: Monitor the resolution of the ongoing IRS audit for the 2023 tax year.